Viking Therapeutics, Inc.
VKTXW
VKTXW was delisted on the 8th of April, 2021.
4 hedge funds and large institutions have $879K invested in Viking Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
40% less capital invested
Capital invested by funds: $1.48M → $879K (-$596K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$153K |
Top Sellers
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$300K |
| 2 |
OFG
OTA Financial Group
Purchase,
New York
|
-$214K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PWAM
1
Park West Asset Management
San Francisco,
California
| $646K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $144K | +$153K | +21,353 | New |
|
|
3
William Blair & Company
Chicago,
Illinois
| $61K | -$300K | -41,910 | -82% |
|
4
UBS Group
Zurich,
Switzerland
| $28K | – | – | – |
|
|
OFG
5
OTA Financial Group
Purchase,
New York
| – | -$214K | -23,883 | Closed |
|
VKTXW Hedge Fund Activity: Q2 2019 in Review
4 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics, Inc. (VKTXW) for Q2 2019, worth a combined $879K — down 40% from $1.48M a quarter earlier.
Fund positioning in VKTXW was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $153K. The largest seller was William Blair & Company, cutting an estimated $300K.
- 4 institutional investors held Viking Therapeutics, Inc. (VKTXW) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $879K of Viking Therapeutics, Inc. stock for Q2 2019, down 40% quarter-over-quarter.
- 1 fund opened new Viking Therapeutics, Inc. positions in Q2 2019 and 1 closed out, a net change of 0 holders.
- The largest Viking Therapeutics, Inc. buyer in Q2 2019 was Susquehanna International Group, an estimated $153K added.
- The largest Viking Therapeutics, Inc. seller in Q2 2019 was William Blair & Company, an estimated $300K sold.
Based on aggregated 13F filings for Q2 2019.